The US Food and Drug Administration has revoked its authorization of Red No. 3 in food, drinks and ingested drugs across the ...
AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...
Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
In his first Senate confirmation hearing to be secretary of the Department of Health and Human Services, Robert F. Kennedy Jr ...
Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...
If confirmed as health secretary, Robert F. Kennedy Jr. would oversee the Food and Drug Administration and other agencies ...
Kennedy, President Donald Trump's pick to run the U.S. Department of Health and Human Services, Senate confirmation hearings are scheduled Wednesday and Thursday, Jan. 29-30.
RFK Jr. said in Wednesday's confirmation hearing that he wants to combat food dyes. 'Crunchy moms' finally feel seen.
Editorial: Not all ‘processed’ food is bad — but Red Dye No. 3 and harmful chemicals don’t belong in what we eat ...
The FDA is moving to standardize how companies test for asbestos in cosmetics with talc. FDA talc testing aims to improve ...
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...